Aida Oncology

Aida Oncology is a private, pre-revenue diagnostics company leveraging machine learning on RNA expression data to predict chemotherapy efficacy, starting with taxanes in breast cancer. The company has presented multiple clinical validation studies at major conferences (ESMO 2025, SABCS) for its multigene signatures. Its business model targets the large, underserved market of chemotherapy selection, aiming to reduce ineffective treatments and improve patient outcomes.

OncoTect: An AI-driven, machine-learning platform that analyzes RNA expression from FFPE tumor biopsies to generate Drug Sensitivity Scores (DSS) predicting response to specific chemotherapy drugs.

Aida positions itself as having no direct competitors offering validated predictive tools for the most widely used chemotherapy drugs. It competes indirectly with broader genomic profiling companies (e.g., Foundation Medicine, Guardant Health) that focus more on targeted therapies and mutations, and with empirical treatment selection based on clinical guidelines alone.